BriaCell Therapeutics Corp. the appointment of Mr. Martin Schmieg to its Board of Directors. Mr. Schmieg, with 35 years of business experience, is a "C" level executive with a diversified background in the global biotech, med-tech and pharmaceutical industries. Mr. Schmieg's early career focused on accounting and financial management responsibilities serving as Chief Financial Officer to privately held Cytometrics Inc., Advanced Bionics Corporation and publicly traded Sirna Therapeutics Inc. and Isolagen Inc. Mr. Schmieg's appointment comes immediately following the resignation of Mr. Isaac Maresky, who has agreed to remain as a consultant for a transition period.